Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT06496789
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Gastric Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

evaluate efficacy and safety of neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer

Key Dates

Start date
May 27, 2023
Status verified
Jun 2024
Primary completion
Dec 30, 2024
Completion
Dec 31, 2024

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Neoadjuvant chemotherapy

Primary Outcome Measure

PCR [ Time Frame: 3 months after the last subject participating in ]

Central Contacts

Related Studies